Chimeric antigen receptor (CAR) T-cell therapy has reshaped the treatment landscape for lymphoid & myeloid malignancies, yet major clinical and implementation challenges persist.
This symposium is part of the American Society of Hematology (ASH) 2025 meeting.
More information on Roswell Park's presence at ASH will be available soon.
This symposium addresses critical unmet needs in the field:
- Optimizing CAR T cells in real-world practice
- Sequencing therapies
- Managing post-relapse scenarios
- Understanding resistance biology
- Expanding access to underserved populations.
Given the rapid evolution of therapies and shifting treatment paradigms, there is an urgent need to equip clinicians and researchers with expert guidance on how to navigate these complex decisions and translate new data into patient-centered care.
Bridging the Gaps in Cell Therapy for Hematological Malignancies: Expert Guidance, Clinical Experience and Increased Access
Moderator: Renier Brentjens, MD, PhD
Co-chairs: Marco Davila, MD, PhD & Renier Brentjens, MD, PhD
American Society of Hematology Annual Meeting
Friday, December 5, 2025
3-6 p.m.
Learning objectives
- Demonstrate selection and sequencing of CAR T cell therapy for patients with B-cell malignancies including mantle cell lymphoma and CLL.
- Analyze mechanisms of CAR T cell treatment failure to inform more effective patient monitoring and management strategies.
- Apply strategies to expand equitable access to CAR T cell therapy including decentralized care models for underserved populations.
- Improve interdisciplinary collaboration and clinical decision-making in the delivery of CAR T cell therapy across diverse practice settings.
Agenda
Time | Topic |
|---|---|
3-3:05 p.m. | Opening Remarks from Moderator |
3:05-3:30 p.m. | How to Incorporate CAR T-Cells in the Management of Mantle Cell Lymphoma |
3:30-3:55 p.m. | Incorporation of CAR T-Cells for Acute and Chronic Leukemias |
3:55-4:20 p.m. | Mechanisms of Treatment Failure CAR T-Cells for Lymphoma and Myeloma |
4:20-4:30 p.m. | Break |
4:30-4:55 p.m. | How to Salvage Patients with Relapsed Disease After CAR T-Cell Therapy |
4:55 - 5:20 p.m. | How to Decentralize and Increase Cell Therapy Access for Underserved Areas |
5:20 - 5:55 p.m. | Q&A Panel with all speakers |
5:55 - 6 p.m. | Closing Remarks |
Register today!
Let us know if you'll be in attendance!
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Roswell Park Comprehensive Cancer Center. Roswell Park is accredited by the ACCME to provide continuing medical education for physicians.
Certification
Roswell Park designates this live activity for a maximum of 3.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Commercial support was received from Bristol Myers Squibb for this ASH satellite symposium.
ASH goals of the symposium
This symposium builds on the foundational content presented during the ASH Annual Meeting by delivering a focused, expert-led deep dive into the most pressing questions surrounding CAR T therapy in B-cell malignancies. The proposed talks move beyond e icacy data to address practical, translational, and systemic implementation issues. The session will foster interaction among clinicians, translational researchers, and health systems experts, promoting cross-disciplinary strategies to improve outcomes and broaden access.
While ASH includes a range of CAR T–focused sessions, this symposium uniquely combines disease-specific application, real-world sequencing strategies, biologic resistance mechanisms, and implementation science. It stands out in its comprehensive, practical approach and its attention to health disparities.
Alignment with the ASH research agenda
This session is directly aligned with multiple pillars of the ASH Agenda for Hematology Research, including:
- Cellular Immunotherapies: Exploring how CAR T cells can be better utilized and improved in clinical settings.
- Drug Resistance: Investigating mechanisms of CAR T failure and strategies for overcoming relapse.
- Health Equity: Addressing geographic and systemic barriers to access with decentralized cell therapy models.
- Precision Medicine: Personalizing treatment sequencing for disease state and prior therapy.
- Health Services Research: Highlighting real-world treatment integration and healthcare delivery challenges in cellular therapy.
Each talk is designed to speak to these research priorities, providing attendees with forward-looking, clinically actionable content.
Financial relationships of planners & presenters
The following planners and presenters have either indicated financial relationships with ineligible companies (any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients) or that no financial relationships exist. Policies and guidelines for identifying and mitigating relevant financial relationships of planners and presenters involved in accredited continuing education are in compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.
All of the relevant financial relationships listed have been mitigated: Renier Brentjens, MD, PhD, Consultant: Bristol Myers Squibb; Gracell Biotechnologies; Atara Biotherapeutics; CoImmune; Triumvira; Cargo Therapeutics Research funding: Bristol Myers Squibb Royalties or patent beneficiary: Bristol Myers Squibb; Caribou Biosciences Scientific Advisory Board member: CoImmune; Triumvira; Cargo Therapeutics. Marco Davila, MD, PhD, Consultant: Bristol Myers Squibb; A2 Biotherapeutics; Adaptive Biotechnology; Caribou Biosciences; CRISPR; Legend Biotech; Sythekine; Kite. Francisco Hernandez-Ilizaliturri, MD, Advisory Board member: Bristol Myers Squibb; Celgene; AbbVie; ADC Therapeutics; Amgen; Collecter; Dava Oncology; Epizyme; Pharmacyclics; BioGene; Gilead; Incyte; Morphosys; Kite; Novartis. Shernan Holtan, MD, Advisory Board member: MaaT Therapeutics Clinical trials adjudication: CSL Behring Consultant: Sanofi; Kadmon Research funding: Vitrac Therapeutics; Incyte